First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, European Center for AngioScience (ECAS), and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany.
Lipids Health Dis. 2019 May 24;18(1):119. doi: 10.1186/s12944-019-1011-x.
The study sought to assess the impact of statin therapy on survival in patients presenting with ventricular tachyarrhythmias.
Data regarding the outcome of patients with statin therapy presenting with ventricular tachyarrhythmias is limited.
A large retrospective registry was used including all consecutive patients presenting with ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016. Patients with statin were compared to patients without statin therapy (non-statin). The primary prognostic endpoint was long-term all-cause death at 3 years. Uni- and multivariable Cox regression analyses were applied in propensity-score matched cohorts.
A total of 424 matched patients was included. The rates of VT and VF were similar in both groups (VT: statin 71% vs. non-statin 68%; VF: statin 29% vs. 32%; p = 0.460). Statin therapy was associated with lower all-cause mortality at long-term follow-up (mortality rates 16% versus 33%; log rank, p = 0.001; HR = 0.438; 95% CI 0.290-0.663; p = 0.001), irrespective of the underlying type of ventricular tachyarrhythmia (VT/VF), left ventricular ejection fraction (LVEF) > 35%, presence of an activated implantable cardioverter defibrillator (ICD), cardiogenic shock or cardiopulmonary resuscitation (CPR).
Statin therapy is independently associated with lower long-term mortality in patients presenting with ventricular tachyarrhythmias on admission.
Clinicaltrials.gov, NCT02982473 , 11/29/2016, Retrospectively registered.
本研究旨在评估他汀类药物治疗对出现室性心动过速/颤动患者生存的影响。
目前关于接受他汀类药物治疗的出现室性心动过速/颤动患者结局的数据有限。
本研究使用大型回顾性队列，纳入了 2002 年至 2016 年期间所有因室性心动过速（VT）或颤动（VF）就诊的连续患者。将接受他汀类药物治疗的患者与未接受他汀类药物治疗的患者（非他汀类药物组）进行比较。主要预后终点为 3 年时的全因死亡。在倾向评分匹配队列中进行单变量和多变量 Cox 回归分析。
共纳入了 424 例匹配患者。两组的 VT 和 VF 发生率相似（VT：他汀类药物组 71%比非他汀类药物组 68%；VF：他汀类药物组 29%比非他汀类药物组 32%；p=0.460）。长期随访时，他汀类药物治疗与较低的全因死亡率相关（死亡率分别为 16%和 33%；log-rank，p=0.001；HR=0.438；95%CI 0.290-0.663；p=0.001），与基础室性心动过速类型（VT/VF）、左心室射血分数（LVEF）>35%、植入式心脏复律除颤器（ICD）激活、心源性休克或心肺复苏（CPR）无关。
入院时出现室性心动过速/颤动的患者接受他汀类药物治疗与长期死亡率降低独立相关。
Clinicaltrials.gov，NCT02982473，11/29/2016，回顾性注册。
Zotero 插件
